STERIS agrees USD 2.10 billion Xodus deal. STERIS stock is valued at USD 21.2 billion

Published on 10/15/2026 at 13:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xodus is expected to add USD 245.00 million in 2026 revenue. STERIS stock costs EUR 192.75 on October 15, 2026, with USD 21.2 billion market value.

Acquisition and earnings calendar

STERIS agreed to acquire Xodus Medical for USD 2.10 billion on October 12, 2026.
Xodus is projected to generate USD 245.00 million in 2026 revenue.
STERIS stock trades at EUR 192.75 at 1:08 p.m. CEST at Lang & Schwarz on October 15, 2026.

Börsen-Editorialfoto mit Händlern vor Bildschirmen und steigenden Charts im Gesundheitssektor — Steris plc IE00BFY8C754 wird redaktionell am Börsenparkett der NYSE mit steigenden Healthcare-Sektor-Charts abgebildet, Illustration mit AI erstellt.

STERIS plc (IE00BFY8C754) stock was trading at EUR 192.75 at Lang & Schwarz at 1:08 p.m. CEST on October 15, 2026. On October 12, 2026, STERIS announced a definitive agreement to acquire Xodus Medical for USD 2.10 billion.

Deal expands surgical consumables

The transaction adds patient-positioning products and other operating-room consumables to STERIS's healthcare portfolio. The company expects the acquisition to close by December 31, 2026, subject to customary conditions and regulatory approvals, while financing is expected to rely primarily on debt.

MedTech Dive reported on October 13, 2026, that Xodus is expected to generate USD 245.00 million in 2026 sales. Its products include the Pink Pad patient-positioning system and the See Sharp laparoscopic cleaning device.

What does Xodus add?

The deal gives STERIS a larger consumables platform alongside its infection-prevention equipment and services. That matters because healthcare consumables can increase recurring product revenue, while the acquisition also broadens the company's exposure to operating-room procedures.

When are the next results?

MarketBeat identifies November 4, 2026, as the expected date for STERIS's second-quarter fiscal 2027 results and November 5, 2026, as the conference call date. Its consensus calls for USD 2.68 earnings per share and USD 1.56 billion in revenue, compared with USD 2.47 earnings per share and USD 1.46 billion in the prior-year quarter.

The latest reported quarter, fiscal first quarter 2027 ended June 30, 2026, produced USD 1.49 billion in revenue and USD 200.10 million in net income. The company profile describes STERIS as a healthcare supplier serving hospitals, pharmaceutical manufacturers and other controlled environments.

Stock valuation sets the context

STERIS had a USD 21.2 billion market capitalization as of October 14, 2026. The NYSE-listed company operates in the Healthcare sector and Medical - Specialties industry, with the Xodus agreement now adding a sizeable acquisition to its fiscal 2027 agenda.

Price stays below recent context

The euro quotation places the stock at EUR 192.75 in afternoon trading on October 15, 2026. The next substantive test is whether the Xodus transaction closes by December 31, 2026, and how management incorporates it into the revised fiscal 2027 outlook.

The further course of trading is shown by the continuously updated real-time quote of STERIS stock.